135 related articles for article (PubMed ID: 28655790)
1. Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
Zhao Y; Ting KK; Li J; Cogger VC; Chen J; Johansson-Percival A; Ngiow SF; Holst J; Grau G; Goel S; Muller T; Dejana E; McCaughan G; Smyth MJ; Ganss R; Vadas MA; Gamble JR
Cancer Res; 2017 Aug; 77(16):4434-4447. PubMed ID: 28655790
[TBL] [Abstract][Full Text] [Related]
2. The VE-Cadherin/β-catenin signalling axis regulates immune cell infiltration into tumours.
Zhao Y; Li J; Ting KK; Chen J; Coleman P; Liu K; Wan L; Moller T; Vadas MA; Gamble JR
Cancer Lett; 2021 Jan; 496():1-15. PubMed ID: 32991950
[TBL] [Abstract][Full Text] [Related]
3. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
4. Targeting miR-27a/VE-cadherin interactions rescues cerebral cavernous malformations in mice.
Li J; Zhao Y; Choi J; Ting KK; Coleman P; Chen J; Cogger VC; Wan L; Shi Z; Moller T; Zheng X; Vadas MA; Gamble JR
PLoS Biol; 2020 Jun; 18(6):e3000734. PubMed ID: 32502201
[TBL] [Abstract][Full Text] [Related]
5. Novel miRNA-based drug CD5-2 reduces liver tumor growth in diethylnitrosamine-treated mice by normalizing tumor vasculature and altering immune infiltrate.
Liu K; Chen J; Zhao Y; Boland J; Ting KK; Lockwood G; McKenzie C; Kench J; Vadas MA; Gamble JR; McCaughan GW
Front Immunol; 2023; 14():1245708. PubMed ID: 37795103
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin.
Menon C; Ghartey A; Canter R; Feldman M; Fraker DL
Ann Surg; 2006 Nov; 244(5):781-91. PubMed ID: 17060772
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
[TBL] [Abstract][Full Text] [Related]
8. Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27.
Young JA; Ting KK; Li J; Moller T; Dunn L; Lu Y; Moses J; Prado-Lourenço L; Khachigian LM; Ng M; Gregory PA; Goodall GJ; Tsykin A; Lichtenstein I; Hahn CN; Tran N; Shackel N; Kench JG; McCaughan G; Vadas MA; Gamble JR
Blood; 2013 Oct; 122(16):2911-9. PubMed ID: 24009229
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
10. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
11. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity.
Ko E; Luo W; Peng L; Wang X; Ferrone S
Cancer Res; 2007 Aug; 67(16):7875-84. PubMed ID: 17699794
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
[TBL] [Abstract][Full Text] [Related]
13. CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions.
Chrifi I; Louzao-Martinez L; Brandt M; van Dijk CGM; Burgisser P; Zhu C; Kros JM; Duncker DJ; Cheng C
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1098-1114. PubMed ID: 28428220
[TBL] [Abstract][Full Text] [Related]
14. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Fankhauser M; Broggi MAS; Potin L; Bordry N; Jeanbart L; Lund AW; Da Costa E; Hauert S; Rincon-Restrepo M; Tremblay C; Cabello E; Homicsko K; Michielin O; Hanahan D; Speiser DE; Swartz MA
Sci Transl Med; 2017 Sep; 9(407):. PubMed ID: 28904226
[TBL] [Abstract][Full Text] [Related]
15. The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation.
Li H; Shi X; Liu J; Hu C; Zhang X; Liu H; Jin J; Opolon P; Vannier JP; Perricaudet M; Janin A; Soria C; Lu H
Cancer Gene Ther; 2010 Oct; 17(10):700-7. PubMed ID: 20559333
[TBL] [Abstract][Full Text] [Related]
16. The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions.
Rezaei M; Cao J; Friedrich K; Kemper B; Brendel O; Grosser M; Adrian M; Baretton G; Breier G; Schnittler HJ
Histochem Cell Biol; 2018 Jan; 149(1):15-30. PubMed ID: 29143117
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
18. Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin.
Zhao Z; Yao Y; Ding Z; Chen X; Xie K; Luo Y; Zhang J; Chen X; Wu X; Xu J; Zhao J; Niu T; Liu J; Li Q; Zhang W; Wen Y; Su J; Hu B; Bu H; Wei Y; Wu Y
Vaccine; 2011 Jun; 29(25):4218-24. PubMed ID: 21497630
[TBL] [Abstract][Full Text] [Related]
19. Role of cadherins in the transendothelial migration of melanoma cells in culture.
Sandig M; Voura EB; Kalnins VI; Siu CH
Cell Motil Cytoskeleton; 1997; 38(4):351-64. PubMed ID: 9415377
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy.
Qian C; Yang C; Tang Y; Zheng W; Zhou Y; Zhang S; Song M; Cheng P; Wei Z; Zhong C; Wan L; Wang A; Zhao Y; Lu Y
Pharmacol Res; 2022 Aug; 182():106333. PubMed ID: 35779815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
